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Finding the right dose of rifampicin, and the right dose of 
optimism
After the widespread introduction of rifampicin in 
the early 1970s, it took another two decades, and 
more than 50 randomised trials with more than 
20 000 participants1 to ﬁ nalise the drugs, doses, and 
schedule for the currently recommended regimen for 
newly diagnosed patients with active tuberculosis. Yet 
this regimen has important drawbacks, most notably 
the 6 months duration, and frequent toxicity. These 
limitations have stimulated considerable research 
interest to ﬁ nd shorter and better-tolerated regimens. 
New drug development is expensive, and progress 
in the past 20 years has been very slow. Investigators 
have re-examined current drugs and doses, including 
the dose of rifampicin, which was initially selected as 
the lowest eﬀ ective dose because this drug was very 
expensive when ﬁ rst introduced. Bacterial clearance in 
mice,2 extended early bactericidal activity in patients 
with pulmonary  tuberculosis,3 and 6-month survival 
in patients with tuberculosis meningitis4 have all 
been improved with higher doses of rifampicin. 
In patients with tuberculosis, meningitis survival 
was closely related to serum concentrations.5 In 
The Lancet Infectious Diseases, Martin Boeree and 
colleagues6 report ﬁ ndings of a randomised controlled 
phase 2B trial of patients with drug-sensitive pulmonary 
tuberculosis. The trial assessed four experimental 
regimens given for 12 weeks followed by 14 weeks of 
isoniazid and rifampicin. The regimen with rifampicin 
dosage of 35 mg/kg (RIF35) resulted in faster time 
to culture conversion compared with the standard 
regimen. This diﬀ erence was not seen with the other 
experimental regimens (including two with rifampicin 
dose of 20 mg/kg), and was seen only with liquid 
culture media, but not solid cultures. Compared 
with the standard regimen, serious adverse events 
including hepatitis were not signiﬁ cantly higher with 
any experimental regimen, although the study was 
underpowered for this outcome, and the occurrence of 
hepatitis with RIF35 was more than twice as high as with 
standard rifampicin doses. 
There are two important methodological issues 
to consider when interpreting this interesting and 
well executed study; use of the innovative multi-
arm, multi-stage (MAMS) design, and time to culture 
conversion as the primary outcome. The MAMS trial 
design has been used successfully in phase 2 cancer trials 
to select regimens for phase 3 trials, and to minimise 
enrolment to regimens with inadequate eﬃ  cacy or 
excessive toxicity.7,8 However, to successfully reduce the 
number of participants enrolled to worse regimens, 
the time from enrolment to outcome in participants 
included in the interim analyses must be substantially 
shorter than the total time to enrol all participants. 
In this trial, 117 participants were randomly assigned 
to the arms that were stopped early, compared with 
127 randomly assigned to the experimental arms 
that were continued—the diﬀ erence represented a 
3% reduction of overall enrolment—a rather modest 
beneﬁ t. 
The other consideration is the critical importance 
in phase 2 trials of the predictive accuracy of the 
intermediate outcome,7 and a high negative predictive 
value is essential to avoid falsely concluding that a 
regimen is inadequate. In this trial, enrolment was 
stopped for two regimens containing SQ109, based on 
the time to culture conversion. But, before concluding 
that SQ109 should not be considered for phase 3 
trials, what is the accuracy of this outcome? Using 
meta-regression techniques, Wallis and colleagues9 
found a relationship between 2-month culture con-
version (a dichotomous outcome) and relapse. This 
spurred highly optimistic thinking about the value 
of phase 2b trials, since dampened by the failure of 
4-month ﬂ uoroquinolone-containing regimens to 
achieve relapse free cure in three independent trials,10–12 
despite promising culture conversion data.13,14 We 
advocate for continued study of SQ109, since Wallis 
and colleagues9 did not estimate negative (or positive) 
predictive values, nor did they examine the relationship 
of relapse free cure with time to culture conversion, the 
outcome used in this trial. 
We believe that a shorter regimen for active 
tuberculosis that is also safe and well tolerated is 
urgently needed. Phase 2 trials can be helpful to 
identify promising regimens, but the intermediate 
outcome of 2 or 3 months culture conversion requires 
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further validation work, before we can conﬁ dently use 
this outcome to plan phase 3 trials. This work would 
also allow use of the more eﬃ  cient MAMS design. 
Boeree and colleagues are very optimistic that high 
dose rifampicin might be useful in shortening current 
treatment for drug sensitive tuberculosis; we share their 
optimism, but in a more limited dose. 
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